amyotrophic lateral sclerosis

News

Phase 3 fail prompts Cytokinetics to abandon ALS drug

There’s been a big disappointment for people with amyotrophic lateral sclerosis (ALS), after Cytokinetics said it was halting a trial of its resedemtiv candidate following

News

Speech analysis tech for ALS gets FDA breakthrough tag

Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough

News

FDA advisors split on Biogen’s ALS therapy

But unanimous vote on biomarker validity could support accelerated approval of tofersen.

News

ALS drug tofersen will face FDA advisors, says Biogen

Biogen will have to make the case for its amyotrophic lateral sclerosis (ALS) therapy tofersen to an FDA advisory committee in March before it gets a decision on approval.

News

Artificial neuron in concept of artificial intelligence. Wall-shaped binary codes make transmission lines of pulses and/or information in an analogy to a microchip. Neural network and data transmission.

Verge Genomics takes AI-sourced drug for ALS into clinic

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing.

News

FDA delays decision on Biogen's ALS hope tofersen

The FDA is planning to take an additional three months to review Biogen's experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April.

Phase 3 fail prompts Cytokinetics to abandon ALS drug

Speech analysis tech for ALS gets FDA breakthrough tag

FDA advisors split on Biogen’s ALS therapy

ALS drug tofersen will face FDA advisors, says Biogen

Verge Genomics takes AI-sourced drug for ALS into clinic

FDA delays decision on Biogen's ALS hope tofersen

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

amyotrophic lateral sclerosis

Editor's Picks